Insider Selling: Natera (NASDAQ:NTRA) Director Sells 2,750 Shares of Stock

Key Points

• Rowan Chapman, a director at Natera, sold 2,750 shares of the company's stock at an average price of $166.99, resulting in a total value of $459,222.50, marking a 31.37% decrease in ownership.
• Natera's stock traded up 0.6%, reaching $169.34, with a market capitalization of $23.24 billion and a negative P/E ratio of -88.66.
• The company reported a (0.74) earnings per share for the last quarter, missing estimates and showing a 32.2% increase in revenue compared to the same quarter last year.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director directly owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Natera Trading Up 0.9%

Shares of NTRA traded up $1.46 during midday trading on Friday, reaching $168.02. The stock had a trading volume of 776,006 shares, compared to its average volume of 1,211,789. The firm has a 50 day simple moving average of $154.35 and a 200-day simple moving average of $153.91. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The firm has a market cap of $23.06 billion, a PE ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an "outperform" rating in a report on Tuesday. Piper Sandler reaffirmed an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Finally, Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price for the company in a report on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.00.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after buying an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company's stock valued at $1,795,125,000 after buying an additional 3,263,822 shares in the last quarter. Norges Bank acquired a new position in shares of Natera in the 2nd quarter valued at approximately $277,749,000. Nuveen LLC acquired a new position in shares of Natera in the 1st quarter valued at approximately $113,375,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after buying an additional 732,156 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.